Johnson & Johnson has received Food and Drug Administration approval to use its Spravato nasal spray as a standalone treatment for adults with major depressive disorder who have shown an inadequate response to at least two oral antidepressants. This marks the first time a medication of this type has been approved in its sole form for this condition.
Spravato, which is closely related to ketamine, was initially approved by the FDA in 2019 as a combination therapy with an oral antidepressant. However, it has seen significant growth in sales over the past year, reaching $780 million for the first nine months of 2024 – a 60% increase from the same period last year.
The medication has been administered to over 140,000 patients worldwide and is expected to provide relief to those struggling with treatment-resistant depression.
Source: https://www.marketwatch.com/story/johnson-johnson-gets-fda-ok-for-spravato-as-monotherapy-3d1b3619